BioAtla Announces Significant Oral Presentation
BioAtla, Inc. (NASDAQ: BCAB), a clinical-stage biotechnology company, has exciting news for those invested in innovative cancer treatments. The company has scheduled an oral presentation that is set to take place at the prestigious European Society for Medical Oncology (ESMO) TAT Asia Meeting. This meeting is known for showcasing cutting-edge research and advancements in the field of oncology.
Details of the Oral Presentation
The focus of this oral presentation will be on a groundbreaking study titled "First-in-human phase I study of a dual-Conditionally Active Biologic (CAB) EpCAM x CD3 bispecific T-cell engager (TCE), BA3182, in patients with treatment refractory metastatic adenocarcinoma." This study is pivotal as it explores a new treatment option for patients facing significant challenges with existing therapies.
Key Contributors to the Study
A team of esteemed professionals in the medical field will present findings from this research. Notable contributors include Jennifer B. Brooke Valerin, Jacob Thomas, J. Eva E. Selfridge, and several others. Their collaboration highlights the importance of multidisciplinary approaches in advancing cancer treatment.
Timing and Venue
This oral presentation is scheduled for July 18, 2025, from 15:59 to 16:06 GMT+8. Attendees of the ESMO TAT Asia Meeting will be able to engage with the data and ask questions following the presentation, which should encourage robust discussion among peers in the oncology community.
About BioAtla's Innovative Technologies
BioAtla is at the forefront of biotechnological advancements focusing on Conditionally Active Biologics (CAB). These innovative therapeutics are specifically designed to target solid tumors effectively while minimizing toxicity. Through this technology, BioAtla aims to revolutionize cancer treatment by offering therapies that are both more efficient and cost-effective.
Future Ventures and Patents
The company boasts a strong patent portfolio, securing a competitive edge in the biotechnology sector. With over 780 active patent matters, more than 500 of which are already issued patents, BioAtla is well-positioned to expand its market presence and maintain its commitment to innovative cancer therapies. This level of patent coverage not only protects their existing products but also assures stakeholders of the company’s ongoing commitment to research and development.
Stay Connected
For those interested in learning more about BioAtla's upcoming presentation, additional materials will eventually be available on the company's official website after the event concludes. This transparency ensures that interested parties have access to the latest research findings and updates directly from BioAtla.
Contact Information
For any inquiries, please reach out to:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
Email: rwaldron@bioatla.com
Phone: 858.356.8945
Mike Moyer
LifeSci Advisors, LLC
Email: mmoyer@lifesciadvisors.com
Frequently Asked Questions
What is BioAtla's primary focus?
BioAtla focuses on developing Conditionally Active Biologics for the treatment of solid tumors.
When and where will the oral presentation take place?
The presentation is scheduled for July 18, 2025, at the ESMO TAT Asia Meeting.
Who are the authors of the study?
Key authors include Jennifer B. Brooke Valerin, Jacob Thomas, and several others.
How does BioAtla protect its innovations?
BioAtla maintains a robust patent portfolio with over 780 active patent matters.
How can I access the presentation materials?
Materials will be accessible on BioAtla's website after the presentation concludes.
